Arimoclomol Citrate

柠檬酸阿利罗莫

Report date: 2026/03/31 20:00:21
NME

Base Information

Drug NameArimoclomol Citrate
Drug Alias NameArimoclomolum阿利罗莫Arimoclomol阿莫氯醇Miplyffa +[11] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionMolecular chaperones modulatorsProtein biosynthesis stimulants
TargetsMolecular chaperones
Therapy Area/IndicationsGaucher's disease type IIIGaucher's disease type IAmyotrophic Lateral Sclerosis +[5] 
Global Approved IndicationsNiemann-Pick Disease, Type C
Approved Indications in ChinaN/A
Original Approved Country/TerritoryUnited States
Original Approved Date2024/09/20
Country/TerritoryBelgiumCanadaUnited States +[15] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaN/A
Originator CompaniesOrphazyme A/S
China Registration ClassN/A

Develop Information

Active CompaniesZevra Therapeutics IncXoma CorpOrphazyme A/S
Inactive CompaniesCytrx CorpUniversity Of Miami
Active IndicationsNiemann-Pick Disease, Type C
Inactive IndicationsGaucher's disease type IIIGaucher's disease type IAmyotrophic Lateral Sclerosis +[4] 

Other Information

ATC CodeN07XX17
Related LinksWikipediaDrugBank